The Risk of Pulmonary Embolism and Deep Vein Thrombosis in Major Rheumatic Diseases
1. To evaluate the risk of pulmonary embolism (PE) and deep vein thrombosis (DVT) in major rheumatic diseases, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), gout, systemic autoimmune rheumatic diseases (SARDs) and osteoarthritis (OA).
2. To evaluate potential anti-thrombotic benefits of anti-rheumatic drugs in major rheumatic diseases.
1. Each major rheumatic disease is independently associated with an increased risk of PE and DVT.
2. Use of anti-rheumatic therapy may reduce the risk of VTE in affected individuals.
The proposed population-based study will be a timely, comprehensive evaluation of risk for PE and DVT among prototypic rheumatic conditions in general population contexts. This studys large-scale yet cost-efficient approach will provide the relevant data on this critical outcome, filling major gaps in our endeavour to improve the overall outcomes in those living with lifelong inflammatory arthritic conditions.